flurazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1218 17617-23-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flurazepam
  • stauroderm
  • flurazepam hydrochloride
  • flurazepam HCl
A benzodiazepine derivative used mainly as a hypnotic.
  • Molecular weight: 387.88
  • Formula: C21H23ClFN3O
  • CLOGP: 4.21
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 35.91
  • ALOGS: -4.59
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 500 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class EIF2AK3,GRK2,PDK1,PDK2,PDK4 5
kinase-selectivity-class PDK4 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
April 7, 1970 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 762.65 42.56 171 2601 24473 90601202
Drug abuse 502.91 42.56 158 2614 82189 90543486
Intentional self-injury 290.34 42.56 82 2690 29252 90596423
Intentional overdose 252.53 42.56 98 2674 93736 90531939
Suicide attempt 243.49 42.56 90 2682 75309 90550366
Toxicity to various agents 148.41 42.56 98 2674 287748 90337927
Bradyphrenia 125.96 42.56 32 2740 7580 90618095
Somnolence 88.10 42.56 63 2709 209021 90416654
Substance abuse 76.15 42.56 20 2752 5386 90620289
Coma 69.51 42.56 37 2735 72595 90553080
Mydriasis 67.57 42.56 23 2749 14989 90610686
Drug interaction 60.65 42.56 57 2715 276396 90349279
Hypokinesia 51.43 42.56 19 2753 15678 90609997
Altered state of consciousness 51.00 42.56 23 2749 31509 90594166
Sedation 44.54 42.56 24 2748 48147 90577528

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 216.73 34.95 95 1461 104676 42515103
Sopor 155.72 34.95 44 1512 13158 42606621
Intentional self-injury 149.58 34.95 44 1512 15158 42604621
Psychomotor hyperactivity 62.71 34.95 21 1535 10937 42608842
Suicide attempt 55.48 34.95 29 1527 46071 42573708
Feelings of worthlessness 50.75 34.95 9 1547 315 42619464
Coma 48.70 34.95 28 1528 53526 42566253
Toxicity to various agents 48.33 34.95 50 1506 229086 42390693
Abulia 43.96 34.95 9 1547 681 42619098
Obsessive-compulsive disorder 38.87 34.95 13 1543 6730 42613049
Restless legs syndrome 38.02 34.95 14 1542 9600 42610179

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 855.52 35.24 211 3994 36335 110548759
Drug abuse 659.73 35.24 248 3957 177163 110407931
Intentional self-injury 442.19 35.24 126 4079 37303 110547791
Suicide attempt 228.66 35.24 100 4105 103294 110481800
Intentional overdose 220.11 35.24 105 4100 132396 110452698
Toxicity to various agents 171.37 35.24 143 4062 480412 110104682
Bradyphrenia 154.12 35.24 43 4162 11685 110573409
Coma 95.33 35.24 58 4147 117811 110467283
Drug interaction 69.52 35.24 90 4115 500093 110085001
Somnolence 63.87 35.24 67 4138 297382 110287712
Hypokinesia 57.64 35.24 24 4181 21802 110563292
Substance abuse 55.37 35.24 20 4185 12443 110572651
Mydriasis 53.96 35.24 23 4182 22134 110562960
Psychomotor hyperactivity 52.55 35.24 22 4183 20255 110564839
Altered state of consciousness 45.61 35.24 28 4177 57598 110527496
Feelings of worthlessness 44.98 35.24 9 4196 581 110584513
Hypotension 39.47 35.24 71 4134 523778 110061316
Bradykinesia 39.42 35.24 15 4190 10773 110574321
Abulia 37.81 35.24 9 4196 1304 110583790
Obsessive-compulsive disorder 37.41 35.24 13 4192 7228 110577866
Overdose 37.03 35.24 45 4160 233749 110351345
Muscle rigidity 36.60 35.24 18 4187 24013 110561081

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD01 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:91016 GABA<small><sub>A</sub></small> receptor agonist
FDA EPC N0000175694 Benzodiazepine

Related Drugs by ATC class:

N05CD Benzodiazepine derivatives 14 drugs
brotizolamcinolazepamdoxefazepamestazolamflunitrazepamloprazolamlormetazepammidazolamnimetazepamnitrazepamquazepamremimazolam show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Disorder of lung contraindication 19829001 DOID:850
Borderline personality disorder contraindication 20010003 DOID:10930
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Decreased respiratory function contraindication 80954004
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Behavioral Disorders contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.24 Basic
pKa2 1.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR IC50 8.10 WOMBAT-PK CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.22 WOMBAT-PK

External reference:

IDSource
4019763 VUID
N0000147854 NUI
D00329 KEGG_DRUG
1172-18-5 SECONDARY_CAS_RN
4017827 VANDF
4019763 VANDF
C0016375 UMLSCUI
CHEBI:5128 CHEBI
FL7 PDB_CHEM_ID
CHEMBL3989724 ChEMBL_ID
CHEMBL968 ChEMBL_ID
DB00690 DRUGBANK_ID
D005479 MESH_DESCRIPTOR_UI
3393 PUBCHEM_CID
7188 IUPHAR_LIGAND_ID
2551 INN_ID
IHP475989U UNII
4501 RXNORM
4752 MMSL
70 MMSL
d00238 MMSL
001463 NDDF
004584 NDDF
19403009 SNOMEDCT_US
27928002 SNOMEDCT_US
387109000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Flurazepam HUMAN PRESCRIPTION DRUG LABEL 1 21695-363 CAPSULE 30 mg ORAL ANDA 19 sections
Flurazepam HUMAN PRESCRIPTION DRUG LABEL 1 52959-236 CAPSULE 30 mg ORAL ANDA 19 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0092 CAPSULE 15 mg ORAL ANDA 14 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0093 CAPSULE 30 mg ORAL ANDA 14 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62135-736 CAPSULE 15 mg ORAL ANDA 20 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62135-737 CAPSULE 30 mg ORAL ANDA 20 sections